Pipeline and Clinical Development - Vopimetostat, a PRMT5 inhibitor, is in dose expansion for MTAP-del cancers and dose escalation for RAS-mut pancreatic and lung cancer, including combinations with RAS inhibitors[13] - TNG456, a brain-penetrant PRMT5 inhibitor, is in dose escalation for MTAP-del glioblastoma[13] - TNG961, an HBS1L degrader, has Phase 1 enabled for MTAP/FOCAD-del solid tumors[13] - A pivotal study for vopimetostat monotherapy in 2L MTAP-del pancreatic cancer is planned to start in 2026[23, 37] - Early data from the vopimetostat + RAS(ON) inhibitor clinical study is encouraging, with 30 patients dosed and both combinations well-tolerated[45, 48] Vopimetostat Clinical Data - Vopimetostat monotherapy demonstrated an Overall Response Rate (ORR) of 27% across 16 different histologies and a Disease Control Rate (DCR) of 78%[30] - In 2L pancreatic cancer, vopimetostat showed a median Progression-Free Survival (mPFS) of 7.2 months, more than twice historical Standard of Care (SOC) trials[32, 35] - In a histology-selective cohort, vopimetostat achieved an ORR of 49%, a DCR of 89%, and an mPFS of 9.1 months[50, 53] Financial Status - The company reported a cash balance of $343 million as of December 31, 2025, providing a cash runway into 2028[19, 81] Glioblastoma Focus - TNG456 is being developed for MTAP-del glioblastoma, which represents 45% of GBM cases, or approximately 7,000 patients per year in the US[23]